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BACKGROUND: Tumor-derived soluble factors serve as mediators between tumors and surrounding microenvironment to promote
tumor growth and metastasis under a complex network. The objective of this study was to evaluate the relationships between soluble
major histocompatibility complex class I chain-related molecule A (sMICA) and 4 categories of cytokines (tumor-related proinflamma-
tory, anti-inflammatory, chemotactic/proangiogenic, and growth-stimulatory) in the development and progression of pancreatic duc-
tal adenocarcinoma (PDAC). METHODS: Serum levels of sMICA and 4-categorized cytokines were measured by enzyme-linked
immunosorbent assay and chemiluminescent immunoassay, respectively, in 134 individuals (normal, n ¼ 55; chronic pancreatitis, n ¼
25; PDAC, n ¼ 54). Clinical implications of sMICA and tumor-related cytokines, their correlations, and diagnostic usefulness in PDAC
were evaluated. RESULTS: Serum sMICA, which was associated with the development and progression of PDAC, correlated with inter-
feron-c negatively (P ¼ 0.024), whereas it correlated positively with the anti-inflammatory cytokines interleukin-10 (IL-10) and IL-1 re-
ceptor antagonist, and the bifunctional cytokine tumor necrosis factor a, with respect to PDAC development (P < .05). sMICA also
correlated positively with the chemotactic/proangiogenic cytokines vascular endothelial growth factor, soluble CD40 ligand, and IL-8,
and the tumor growth-stimulatory cytokines epidermal growth factor and transforming growth factor a, with respect to PDAC devel-
opment and/or progression. Logistic regression analysis validated the diagnostic usefulness of combination use of sMICA and
its related cytokines to predict the presence of PDAC and distant metastasis in PDAC, superior to carbohydrate antigen 19-9.
CONCLUSIONS: sMICA may be involved in tumor-associated angiogenesis and tumor growth either directly or indirectly by affecting
corresponding cytokines as well as causing impairment of natural killer cell cytotoxicity in the development and progression of PDAC.
A combination of sMICA and its related cytokines exhibited remarkable diagnostic potential in PDAC. Cancer 2013;119:233-44.VC 2012
American Cancer Society.
KEYWORDS: cytokines, diagnostic accuracy, pancreatic ductal adenocarcinoma, relationship, soluble major histocompatibility
complex class I chain-related molecule A.
Tumors in immunocompetent hosts are forced to develop and grow despite constant pressure from the immune system,
consisting of cytotoxic immune cells and multiple soluble mediators such as cytokines and chemokines.1 However, tumor
cells can reprogram normal stroma to immunosuppressive tumorigenic stroma, which allows them to escape antitumor
immunosurveillance, and ultimately leads to the development or evolution of the malignant process by the aberrant pro-
duction of soluble mediators, which induce an imbalance between proinflammatory and anti-inflammatory cytokines.2,3
Tumor-derived cytokines also serve as paracrine or autocrine growth factors to promote tumor growth and tumor-
associated angiogenesis, which are critical steps for tumor expansion and acquisition of metastatic potential.4
Natural killer (NK) cells are the primary critical effectors in anti-tumor immunity.5 They are mainly activated by
natural killer group 2 member D (NKG2D) receptors.6 In humans, major histocompatibility complex class I-related
molecule A (MICA) and B (MICB) are major ligands of NKG2D, which are widely up-regulated on tumor surfaces in
response to malignant transformation, thereby leading to tumor cell lysis and cytokine secretion induced by NK or T
cells.6 However, MICA/MICB proteins can be shed from the tumor cell surface into the extracellular milieu as a cytokine-
like soluble form, impairing the cytotoxic response against tumors by reducingMICA/MICB expression on the tumor cell
surface and down-regulating NKG2D on NK and T cells via internalization and degradation.7 These immune escape
strategies may influence tumor development and progression.8 However, other mechanisms may exist in the sMICA/
sMICB-associated tumorigenicity and invasiveness of cancer beyond these immune escape strategies.
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Pancreatic ductal adenocarcinoma (PDAC) is char-
acterized as being surrounded by a dense desmoplastic
microenvironment that produces multiple immunosup-
pressive cytokines, which can provide several immunolog-
ical advantages that allow cancer cells to escape host
antitumor immunity.3,9-11 PDAC also produces multiple
protumorigenic growth factors such as proangiogenic and
growth-stimulatory cytokines.12 Thus, cytokines may
play crucial roles in the malignant transformation and
evolution of PDAC, allowing it to become an intractable
and aggressive disease.
In PDAC, MICA proteins also can be released from
the cell surface into the extracellular tumor microenviron-
ment; the resulting elevation of serum sMICA can affect
the development and evolution of PDAC13,14 through
direct impairment of NK cell function via a decrease in
MICA expression on the PDAC surface and down-regula-
tion of NKG2D on NK cells.7 However, circulating
sMICAmay interact with other soluble mediators, such as
immune-related or protumorigenic cytokines produced
by PDAC, which can affect the development and progres-
sion of PDAC. In general, soluble mediators in the tumor
microenvironment are connected with one another.15 In
addition, the NKG2D-MICA system is interrelated with
several cytokines and chemokines for the activation of NK
cells and the proper expression of MICA on the cell sur-
face.16 Thus, exploration of the relationship between
sMICA and dysregulated cytokines produced by PDAC
along the carcinogenic process of this cancer can help to
understand the detailed mechanism of sMICA-associated
tumorigenicity and the evolution of PDAC, and can pro-
vide valuable information for effective diagnostic and
therapeutic strategies for PDAC with respect to cancer
immunology.
In this study, we evaluated the correlations between
sMICA and 4 categories of cytokines (proinflammatory,
anti-inflammatory, chemotactic/proangiogenic, and
tumor growth-stimulatory cytokines) along the PDAC
carcinogenic process, and clarified their clinical implica-
tions and diagnostic usefulness in PDAC using serum
samples obtained from normal, chronic pancreatitis (CP),
and PDAC subjects.
MATERIALS AND METHODS
Study Population
The study groups were composed of 55 healthy volun-
teers, 25 patients with CP, and 54 patients with PDAC
who visited the Yonsei University Health System, Seoul,
Korea, to allow for a statistical power greater than 0.8
with a statistical significance (a) of 0.05 by F-test (1-way
ANOVA). All participants underwent medical history
assessment, physical exam, chemical tests, and abdominal
sonography. To confirm CP or PDAC, further radiologic
tests such as computed tomography (CT) and histopatho-
logical tests were performed. Recruitment to each group
was consecutively performed on the basis of these test
results.
For the healthy group, sex- and age-matched healthy
individuals who received a regular checkup and were
revealed to have a normal pancreas without any risk fac-
tors of PDAC and abnormal lab findings were enrolled.
For the CP and PDAC groups, patients with typical
radiological and/or histopathological findings of CP or
PDAC were enrolled, respectively. Other pancreatic
malignancies except ductal adenocarcinoma were
excluded. Patients who suffered from other acute or
chronic illness, fever within 1 week, or other cancers were
excluded. Individuals who received any medications or
treatments for corresponding diseases were also excluded.
Tumor-node-metastasis (TNM) classification of
PDAC was analyzed according to the American Joint
Committee on Cancer (AJCC) Cancer Staging Manual,
6th edition. A pathologist at the Yonsei University Health
System reviewed all histopathological information. Blood
samples for index tests (serum levels of sMICA or cyto-
kines) were prospectively collected at the time of recruit-
ment based on the reference standard (diagnosis) and
before beginning the corresponding treatments. Collected
blood samples were stored at80C as the serum fraction
until analysis. The Institutional Review Board of the
Yonsei University Health System approved this research,
and all participants provided written informed consent.
Measurement of Serum sMICA Levels Using
Enzyme-Linked Immunosorbent Assay
Serum sMICA was detected using a sandwich ELISA as
described.13,14 In brief, monoclonal antibodies (mAbs)
AMO1 and BAMO3 were used at 5.0 and 1.0 lg/mL,
respectively, with recombinant sMICA*04 as the stand-
ard. Plates were coated with the capture mAb and then
blocked by the addition of 15% BSA, washed, and incu-
bated with normal or patient serum overnight at 4C.
Anti-mouse IgG2a-HRP (1:8,000 dilution; Southern
Biotechnologies, Birmingham, Alabama) was used as the
secondary antibody and the reaction was developed using
the TMB peroxidase substrate system (KPL, Gaithers-
burg, Maryland). Absorbance was measured at 450 nm,
and results were calculated using a calibration curve pre-
pared from standards.
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Measurement of Serum 4-Categorized
Cytokines Levels Using a Chemiluminescent
Immunoassay
Twenty tested cytokines were classified into 4 categories
as follows: proinflammatory cytokines with antitumor ac-
tivity comprising interleukin-1a (IL-1a), IL-1b, IL-2, IL-
6, IL-12p70, IL-15, tumor necrosis factor-a (TNF-a),
interferon-a (IFN-a), and IFN-c; anti-inflammatory
cytokines with protumorigenic activity comprising IL-4,
IL-10, IL-13, and IL-1 receptor antagonist (IL-1RA); che-
motactic/proangiogenic cytokines comprising monocyte
chemoattractant protein-1 (MCP-1, also known as
CCL2), interferon-inducible protein (IP)-10 (also known
as CXCL10), vascular endothelial growth factor (VEGF),
soluble CD40 ligand (sCD40L), and IL-8 (also known as
CXCL8); and growth-stimulatory cytokines comprising
epidermal growth factor (EGF) and transforming growth
factor-a (TGF-a). These classifications are not absolute,
because many of these cytokines are pleiotropic and have
overlapping activities.
Cytokines were measured using a commercially
available MILLIPLEX MAP Human Cytokine/Chemo-
kine Kit (Millipore, Billerica, Massachusetts). This kit
allowed for the simultaneous quantification of all 20
tested cytokines. Briefly, the filter plate was prewetted
with 200 lL assay buffer for 10 minutes at room tempera-
ture (RT), followed by vacuum removal of the assay
buffer. Standard or control (25 lL) was added into the
appropriate well, and 25 lL of assay buffer was added to
the sample wells but not to the background well. Next, 25
lL of the appropriate matrix solution was added to the
background, standard, and control wells, followed by the
addition of 25 lL of sample into the appropriate wells.
After mixing, 25 lL of beads were added and the plate
was incubated overnight at 4C with shaking. After incu-
bation, the fluid was removed and the plate was washed
twice. Detection antibodies (25 lL) were added, and the
plate was incubated for 1 hour at RT with shaking. Strep-
tavidin-phycoerythrin (25 lL) was added to each well
containing 25 lL of detection antibodies and was incu-
bated for 1 hour at RT with shaking. The fluid was then
removed, the plate was washed, and 150 lL of sheath fluid
was added. After resuspension for 5 minutes, the median
fluorescent intensity (MFI) data were read on a Luminex
100 IS and analyzed using the logistic curve-fitting
method to determine cytokine concentrations.
Measurement of Serum CA19-9 Levels
Serum CA 19-9 levels were measured using a Vitros-3600
automatic analyzer (Ortho Clinical Diagnostic, New
York, New York) for comparison of cytokine diagnostic
accuracy.
Statistical Analysis
All assays were performed in duplicate in a blinded fash-
ion on the same day (1 month after the end date of recruit-
ment, November 30, 2011) by a PhD who is an expert in
this field. Each value is expressed as the mean of 2 deter-
minations. All of the serum samples from the subjects
recruited in this study were included in the final analysis.
The Kruskal-Wallis test was used to compare serum levels
of each tested value among more than 3 groups. Mann-
Whitney U test was used to compare serum levels of each
tested value between 2 groups. PDAC group was subdi-
vided into 2 groups according to the presence or absence
of distant metastasis: PDAC without metastasis (PDAC/
M0) and PDAC with metastasis (PDAC/M1). Spear-
man’s correlation analysis was performed to assess the cor-
relations between soluble mediators and non-continuous
variables, and Pearson’s correlation analysis was per-
formed to assess the correlations among soluble media-
tors. Receiver operator characteristic (ROC) curves were
generated to calculate the area under the curve (AUC) to
determine the cutoff point for the best sensitivity/specific-
ity in order to predict the presence of PDAC or its distant
metastasis. To confirm the diagnostic potential of the
combined use of sMICA and specific cytokines in PDAC,
we performed logistic regression analysis. P values <.05
were considered statistically significant. Statistical analyses
were performed with SPSS version 13.0 software (SPSS,
Chicago, Illinois).
We validated the final conclusions using independ-
ent test samples (validation dataset) to estimate the repro-
ducibility of the results. Minimal sample size of each
group for validation (noncancer vs PDAC/M0 vs PDAC/
M1) was calculated to be 13, under the setting that there
were 3 treatment groups, standard deviation within each
group was 0.75, statistical significance was 0.05, and the
statistical power was greater than 0.8 (by ANOVA test).
RESULTS
Serum Levels of sMICA and the 4-Categorized
Cytokines According to Disease Groups
Serum levels of sMICA and cytokines from the 4 different
functional categories were compared among disease
groups (Table 1). Serum sMICA was significantly higher
in PDAC groups compared with the normal group (7.08
 6.8 pg/ml, Kruskal-Wallis, P < .05) and CP group
(44.10  56.4 pg/ml, P < .05), and it was higher in
the PDAC/M1 group (238.49  19.1 pg/mL)
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compared with the PDAC/M0 group (133.00  67.1
pg/mL, P< .05).
We also found that serum levels of several proin-
flammatory cytokines including IL-2, IL-12p70, and
IFN-c were significantly reduced in the CP and PDAC
groups compared with corresponding normal individuals
(Kruskal-Wallis, all P < .05; Table 1), and these 3 cyto-
kines were lower in cancer groups compared with non-
cancer groups (Mann-Whitney U, all P < .05). Between
the PDAC/M0 and PDAC/M1 groups, there was no
significant difference in these 3 cytokines (all P > .05;
Table 1).
On the other hand, serum levels of several anti-
inflammatory cytokines including IL-10 and IL-1RA
were significantly elevated in PDAC groups compared to
CP and normal groups (Kruskal-Wallis, all P< .05; Table
1). These cytokines were slightly higher in the PDAC/M1
group compared to the PDAC/M0 group, although the
difference was not significant (P> .05).
Serum levels of IL-6 and TNF-a, which have
bifunctional immune activities, were significantly elevated
in PDAC groups compared to the CP and normal groups
(Kruskal-Wallis, all P < .05). These 2 cytokines demon-
strated a tendency to be slightly higher in the PDAC/M1
group compared to the PDAC/M0 group.
Serum levels of IP-10, sCD40L, and IL-8, which are
generally considered as chemotactic and/or proangiogenic
cytokines, were significantly different among disease groups
(Kruskal-Wallis, all P < .05; Table 1). IP-10 and sCD40L
were significantly higher in cancer groups compared with
noncancer groups (Mann-Whitney U, all P< .05), whereas
they were not significantly different between PDAC/M0
and PDAC/M1 groups (P > .05). IL-8 was significantly
higher in the PDAC/M1 group compared to the PDAC/
Table 1. Serum Levels of sMICA and 4-Categorized Cytokines According to Disease Groups
Soluble Factors Normal
(n 5 55)
CP
(n 5 25)
PDAC/M0
(n 5 31)
PDAC/M1
(n 5 23)
Kruskal-Wallisa
(P)
NK cell-related
sMICA (pg/mL) 7.08  6.8 44.10  56.4 133.00  67.1 238.49  19.1 <.001
Proinflammatory
IL-1a (ng/mL) 3.39  1.9 0.10  0.1 4.53  24.1 0.10  0.1 .094
IL-1b (ng/mL) 16.80  107.2 0.72  3.1 0.05  0.2 3.18  13.8 .459
IL-2 (ng/mL) 6.69  20.8 1.17  1.9 0.03  0.1 0.02  0.1 <.001
IL-12 (ng/mL) 23.51  135.5 0.91  2.7 3.49  13.3 1.14  4.0 .001
IL-15 (ng/mL) 3.08  13.2 0.70  1.3 3.32  2.2 4.07  4.1 .430
IFN-a (ng/mL) 11.77  18.3 10.67  16.7 23.92  32.1 19.75  25.4 .359
IFN-c (ng/mL) 14.21  22.4 3.35  6.3 2.37  4.2 2.28  4.5 <.001
Anti-inflammatory
IL-4 (ng/mL) 0.10  0.7 0.01  0.1 0.01  0.1 0.01  0.1 .594
IL-10 (ng/mL) 4.81  17.0 2.32  5.4 13.05  32.8 21.15  57.0 <.001
IL-13 (ng/mL) 1.32  9.3 0.01  0.1 0.01  0.1 0.01  0.5 .576
IL-1RA (ng/mL) 5.67  23.0 8.20  31.7 40.44128.2 95.95  350.7 .001
Bifunctional
IL-6 (ng/mL) 4.42  12.5 1.83  21.7 18.55  31.3 74.53  292.3 <.001
TNF-a (ng/mL) 7.39  8.8 5.52  3.8 13.14  7.4 16.45  20.3 <.001
Chemotactic/angiogenic
MCP-1 (ng/mL) 505.54  184.1 489.75  123.9 620.24  476.3 1006.95  213.2 .124
IP10 (ng/mL) 710.14  178.2 542.45  696.4 819.14  723.5 772.42  582.5 <.001
VEGF (ng/mL) 186.67  198.7 142.11  206.5 244.82  261.2 316.64  359.1 .206
sCD40L (ng/mL) 11554.15  483.9 18648.82  102.7 24590.95  622.4 28291.95  420.7 <.001
IL-8 (ng/mL) 55.85  96.4 22.45  36.3 39.44  65.0 1117.08  199.9 <.001
Growth-stimulatory
EGF (ng/mL) 120.62  113.5 251.80  211.2 340.00  325.7 462.87  356.3 <.001
TGF-a (ng/mL) 8.36  9.5 6.78  7.5 9.88  11.2 14.25  11.4 .002
Abbreviations: CP, chronic pancreatitis; EGF, epidermal growth factor; IFN-a, interferon-a; IL-1a, interleukin 1a; IL-1RA, IL-1 receptor antagonist; IP-10, inter-
feron gamma-induced protein 10; MCP-1, monocyte chemotactic protein-1; NK cells, natural killer cells; PDAC, pancreatic ductal adenocarcinoma; PDAC/M0,
PDAC without distant metastasis; PDAC/M1, PDAC with distant metastasis; sCD40L, soluble CD40 ligand; sMICA, soluble MICA; TGF-a, transforming growth
factor-a; TNF-a, tumor necrosis factor-a; VEGF, vascular endothelial growth factor.
Serum levels of sMICA and cytokines were expressed as mean  standard deviation.
a Statistical analysis was performed using a Kruskal-Wallis test. P < .05 (2-tailed) was considered to be statistically significant.
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M0 group, although it was not significantly different
between the cancer and noncancer groups (Table 1). Serum
levels of MCP-1 and VEGF demonstrated a tendency to be
elevated in cancer groups compared with noncancer groups.
Serum levels of EGF and TGF-a, the major growth
factors of PDAC,12 were also significantly elevated along
the PDAC development and progression process (Krus-
kal-Wallis, all P < .05; Table 1). They were significantly
higher in the PDAC/M1 group compared to the PDAC/
M0 group (all P< .05).
Soluble Mediators Correlated With the
Development and Progression of PDAC
Next, we evaluated the correlations between tested
soluble mediators and the development of PDAC.
Among the tested soluble mediators, IL-2, IL-12p70,
and IFN-c (proinflammatory cytokines) showed strong
negative correlations with the development of PDAC
(Spearman’s correlation, all P < .05; Table 2). On the
other hand, IL-10 and IL-1RA (anti-inflammatory
cytokines) as well as IL-6 and TNF-a (bifunctional
proinflammatory cytokines) correlated positively with
the development of PDAC (Spearman’s correlation, all
P < .05; Table 2). sMICA also correlated positively
with the development of PDAC (P < .05). In addi-
tion, IP-10, VEGF, and sCD40L (chemotactic/proan-
giogenic cytokines) as well as EGF and TGF-a
(growth-stimulatory cytokines) showed a strong positive
correlation with the development of PDAC (Spear-
man’s correlation, all P < .05).
Table 2. Spearman’s Correlations Between Soluble Immune Mediators, Including sMICA and 4-Categorized Cytokines, and the
Development or Progression Parameters of Pancreatic Ductal Adenocarcinoma
Soluble Factors PDAC
Development
cs (P)
Size
cs (P)
T Stage
cs (P)
Node
Metastasis
cs (P)
Distant
Metastasis
cs (P)
NK cell-related
sMICA 0.732 (<.001) 0.051 (.724) 0.095 (.510) 0.021 (.887) 0.341 (.015)
Proinflammatory
IL-1a 0.082 (.330) 0.038 (.764) 0.047 (.711) 0.212 (.090)a 0.257 (.058)a
IL-1b 0.098 (.248) 0.044 (.727) 0.003 (.980) 0.119 (.346) 0.044 (.729)
IL-2 0.878 (<.001) 0.005 (.971) 0.055 (.671) 0.198 (.122) 0.046 (.720)
IL-12 0.280 (.001) 0.060 (.633) 0.032 (.803) 0.035 (.779) 0.116 (.357)
IL-15 0.088 (.296) 0.024 (.852) 0.133 (.290) 0.040 (.754) 0.042 (.737)
IFN-a 0.136 (.107) 0.085 (.501) 0.032 (.803) 0.162 (.198) 0.085 (.501)
IFN-c 0.325 (<.001) 0.249 (.051)a 0.021 (.869) 0.158 (.219) 0.092 (.479)
Anti-inflammatory
IL-4 0.077 (.360) 0.002 (.998) 0.003 (.980) 0.011 (.901) 0.031 (.833)
IL-10 0.710 (<.001) 0.037 (.768) 0.167 (.185) 0.209 (.094)a 0.085 (.503)
IL-13 0.009 (.913) 0.082 (.515) 0.109 (.387) 0.077 (.540) 0.144 (.253)
IL-1RA 0.345 (<.001) 0.041 (.747) 0.181 (.149) 0.065 (.610) 0.076 (.548)
Bifunctional
IL-6 0.508 (<.001) 0.052 (.681) 0.167 (.184) 0.058 (.647) 0.020 (.875)
TNF-a 0.645 (<.001) 0.082 (.516) 0.213 (.100) 0.148 (.241) 0.058 (.646)
Chemotactic/angiogenic
MCP-1 0.155 (.065)a 0.068 (.592) 0.091 (.473) 0.209 (.095)a 0.160 (.204)
IP10 0.455 (<.001) 0.175 (.163) 0.188 (.134) 0.070 (.582) 0.081 (.521)
VEGF 0.223 (.010) 0.244 (.072)a 0.031 (.820) 0.203 (.138) 0.252 (.044)
sCD40L 0.519 (<.001) 0.140 (.267) 0.111 (.377) 0.031 (.805) 0.144 (.252)
IL-8 0.131 (.126) 0.281 (.028) 0.070 (.586) 0.071 (.589) 0.469 (.001)
Growth-stimulatory
EGF 0.446 (<.001) 0.154 (.221) 0.080 (.527) 0.216 (.084)a 0.261 (0.036)
TGF-a 0.234 (.005) 0.221 (.076)a 0.029 (.817) 0.149 (.238) 0.278 (0.025)
Abbreviations: EGF, epidermal growth factor; cs, Spearman’s correlation coefficient; IFN-a, interferon-a; IL-1a, interleukin 1a; IL-1RA, IL-1 receptor antagonist;
IP-10, interferon gamma-induced protein 10; MCP-1, monocyte chemotactic protein-1; NK cells, natural killer cells; PDAC, pancreatic ductal adenocarcinoma;
sCD40L, soluble CD40 ligand; sMICA, soluble MICA; TGF-a, transforming growth factor-a; TNF-a, tumor necrosis factor-a; VEGF, vascular endothelial growth
factor.
Statistical analysis was performed by Spearman’s correlation test.
P < .05 (2-tailed) was considered to be statistically significant.
Bold P values are statistically significant.
a This value shows a tendency to be correlated with indicated paramenters although it is not statistically significant.
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Figure 1. Linear regression graphs between soluble major histocompatibility complex class I chain-related molecule A (sMICA)
and cytokines (epidermal growth factor [EGF], interleukin-8 [IL-8], interleukin-10 [IL-10], interleukin-1 receptor antagonist [IL-
1RA], inducible protein-10 [IP10], soluble CD40 ligand [sCD40L], transforming growth factor-a [TGF-a], tumor necrosis factor-a
[TNF-a], vascular endothelial growth factor [VEGF]) related to the development or progression of pancreatic ductal adenocarci-
noma (PDAC) when serum samples were analyzed from all subjects—(A) immune-related, (B) proangiogenic or growth-stimula-
tory cytokines—and (C) from overt PDAC patients.
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We also evaluated the correlations between serum
levels of soluble mediators and pathological parameters of
PDAC including size and TNM stage, reflecting the pro-
gression of PDAC. Most immune-associated cytokines
including proinflammatory, anti-inflammatory, and
bifunctional cytokines were not found to be involved in
the progression of PDAC in this study; although IL-1a
and IFN-c demonstrated a tendency toward correlating
with distant metastasis and tumor size, respectively (Table
2). On the other hand, VEGF and IL-8 (proangiogenic
cytokines), EGF and TGF-a (growth-stimulatory cyto-
kines), and sMICA showed meaningful correlations with
the progression parameters of PDAC (Spearman’s correla-
tion, all P< .05; Table 2).
Correlations Between Serum sMICA and Cytokines
in the Development and Progression of PDAC
We evaluated the correlations between sMICA and spe-
cific cytokines that were meaningful in the development
of PDAC using serum samples from all subjects. The lin-
ear regression graphs showed that IFN-c (proinflamma-
tory) correlated with sMICA negatively, whereas IL-10
and IL-1RA (anti-inflammatory) as well as TNF-a
(bifunctional) correlated with sMICA positively (Fig.
1A). IP-10, VEGF, sCD40L, and IL-8 (chemotactic/
angiogenic cytokines) as well as EGF and TGF-a
(growth-stimulatory cytokines) also correlated with
sMICA positively (Fig. 1B). These results reflect that
sMICA may have a relationship with these PDAC devel-
opment-associated cytokines.
Next, we investigated cytokines related to sMICA in
aspect of PDAC progression using serum samples from
overt PDAC patients. No immune-associated cytokines
correlated with sMICA with respect to the progression of
PDAC. On the other hand, VEGF, IL-8, EGF, and TGF-
a, which are proangiogenic or growth-stimulatory cyto-
kines, were closely related with sMICA with respect to the
progression of PDAC (Fig. 1C).
Taken together, these findings indicate that, among
the 20 tested cytokines, sMICA correlated with 10 cytokines
(IFN-c, IL-10, IL-1RA, TNF-a, IP-10, VEGF, sCD40L,
IL-8, EGF, and TGF-a) when all subjects were analyzed,
which may reflect the development of PDAC, whereas
sMICA was correlated with 4 cytokines (VEGF, IL-8, EGF,
Figure 1. (Continued)
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and TGF-a) when only PDAC patients were analyzed,
which may reflect the progression of PDAC (Fig. 1).
Diagnostic Validity of Combined Use of Serum
sMICA and Cytokines to Predict the Presence of
PDAC and Its Distant Metastasis
Finally, we evaluated the diagnostic usefulness of serum
sMICA and cytokines combination for PDAC, compared
with CA19-9 (Tables 3, 4, and 5; Fig. 2). At first, we eval-
uated the diagnostic potential of serum sMICA and cyto-
kines, which were meaningful in PDAC development, to
predict the presence of PDAC as a single or multiple-
marker panel using logistic regression analysis. ROC
curves were generated for 5 selected soluble factors
(sMICA, IL-10, TNF-a, sCD40L, and IP-10), which
were related with PDAC development and whose AUC
value was above that of CA19-9, for the prediction of
PDAC (Fig. 2A). Logistic regression analysis demon-
strated the 5 selected soluble factors showed superior or
similar sensitivity/specificity for predicting the presence of
PDAC as a single marker, compared to CA19-9. As multi-
ple-marker panels, almost all combinations exhibited
superior predictive utility for the presence of PDAC com-
pared to CA19-9 (Table 3). In particular, the combina-
tion of sMICA, TNF-a, sCD40L, and IP-10
demonstrated the best predictability for the presence of
PDAC (95.5% sensitivity at 80% specificity; Table 3).
We also evaluated the diagnostic potential of serum
sMICA and cytokines, which were associated with distant
metastasis in relation to sMICA, for predicting distant
metastasis in PDAC. ROC curves and logistic regression
results demonstrated these soluble mediators were not
superior in diagnostic potential for predicting distant
Table 4. Diagnostic Accuracy of Combination Use of Serum
sMICA and Specific Cytokines Related With PDAC
Progression to Predict the Presence of Distant Metastasis in
PDAC
Variables Sensitivity Specificity
CA19-9 70.3% 64.3%
Single-marker panel
sMICA 78.6% 63.6%
VEGF 45.9% 66.7%
IL-8 70.3% 66.7%
EGF 54.1% 64.3%
TGF-a 59.5% 67.9%
Two-marker panel
sMICA, VEGF 78.6% 70.6%
sMICA, IL-8 75.0% 68.4%
sMICA, EGF 67.0% 68.2%
sMICA, TGF-a 64.3% 68.2%
Three-marker panel
sMICA, VEGF, IL-8 89.3% 85.7%
sMICA, VEGF, EGF 67.9% 82.4%
sMICA, VEGF, TGF-a 67.9% 82.4%
sMICA, IL-8, EGF 75.0% 84.2%
sMICA, IL-8, TGF-a 57.1% 84.2%
sMICA, EGF, TGF-a 53.6% 77.3%
Four-marker panel
sMICA, VEGF, IL-8, EGF 82.1% 85.7%
sMICA, VEGF, IL-8, TGF-a 89.3% 85.7%
sMICA, IL-8, EGF, TGF-a 71.4% 84.2%
Five-marker panel
sMICA, VEGF, IL-8, EGF, TGF-a 89.3% 85.7%
Abbreviations: CA19-9, carbohydrate antigen 19-9; EGF, epidermal growth
factor; cs, Spearman’s correlation coefficient; IFN-a, interferon-a; IL-1a,
interleukin 1a; IL-1RA, IL-1 receptor antagonist; IP-10, interferon gamma-
induced protein 10; MCP-1, monocyte chemotactic protein-1; PDAC, pan-
creatic ductal adenocarcinoma; sCD40L, soluble CD40 ligand; sMICA, solu-
ble MICA; TGF-a, transforming growth factor-a; TNF-a, tumor necrosis
factor-a; VEGF, vascular endothelial growth factor.
Table 3. Diagnostic Accuracy of Combination Use of Serum
sMICA and Specific Cytokines Related With Pancreatic Ductal
Adenocarcinoma (PDAC) Development to Predict the
Presence of PDAC
Variables Sensitivity Specificity
CA19-9 77.8% 76.9%
Single-marker panel
sMICA 83.0% 80.0%
IL-10 87.0% 80.0%
TNF-a 83.1% 81.5%
sCD40L 75.3% 80.0%
IP-10 61.0% 81.5%
Two-marker panel
sMICA, IL-10 84.8% 80.0%
sMICA, TNF-a 86.4% 80.0%
sMICA, sCD40L 92.4% 80.0%
sMICA, IP-10 87.9% 80.0%
Three-marker panel
sMICA, IL-10, TNF-a 84.8% 80.0%
sMICA, IL-10, sCD40L 92.4% 80.0%
sMICA, IL-10, IP-10 87.9% 80.0%
sMICA, TNF-a, sCD40L 93.9% 80.0%
sMICA, TNF-a, IP-10 92.4% 80.0%
sMICA, sCD40L, IP-10 93.9% 80.0%
Four-marker panel
sMICA, IL-10, TNF-a, sCD40L 90.9% 80.0%
sMICA, IL-10, TNF-a, IP-10 92.4% 80.0%
sMICA, TNF-a, sCD40L, IP-10 95.5% 80.0%
Five-marker panel
sMICA, IL-2, IL-10,
TNF-a, sCD40L
90.9% 80.0%
Abbreviations: CA19-9, carbohydrate antigen 19-9; EGF, epidermal growth
factor; cs, Spearman’s correlation coefficient; IFN-a, interferon-a; IL-1a,
interleukin 1a; IL-1RA, IL-1 receptor antagonist; IP-10, interferon gamma-
induced protein 10; MCP-1, monocyte chemotactic protein-1; PDAC, pan-
creatic ductal adenocarcinoma; sCD40L, soluble CD40 ligand; sMICA, solu-
ble MICA; TGF-a, transforming growth factor-a; TNF-a, tumor necrosis
factor-a; VEGF, vascular endothelial growth factor.
For comparison among various-sized subpanels, the cut-point ensured a
target specificity of around 80%.
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metastasis in PDAC compared to CA19-9 (70.3% sensi-
tivity at 64.3% specificity) as a single marker (Table 4;
Fig. 2B). However, they showed superior predictive abil-
ities as multiple-marker panels compared to CA19-9 in
almost all cases (Table 4). Especially, the combination of
sMICA, VEGF, and IL-8 exhibited up to 90% sensitivity/
specificity for predicting distant metastasis in PDAC
(89.3% sensitivity at 85.7% specificity; Table 4).
Because the differentiation between CP and PDAC
is sometimes difficult in clinics, we evaluated whether
combination use of sMICA and cytokines were useful for
differentiating CP and PDAC. Logistic regression was
performed using the 4 selected soluble factors (sMICA,
IL-10, TNF-a, and IP-10), whose AUC value for differ-
entiating CP and PDAC was above that of CA19-9 (Fig.
2C), and demonstrated superior sensitivity/specificity for
differentiating between CP and PDAC compared to those
of CA19-9 in almost all combinations (Table 5).
Validation of Diagnostic Usefulness of
Combination Use of Serum sMICA and Cytokines
Using Independent Validation Dataset
Overall expression patterns of sMICA and cytokines
according to disease groups, and their correlations were
similar to original results in validation dataset (data not
shown). The diagnostic potential for the presence and dis-
tant metastasis of PDAC were also superior to CA19-9 in
almost all cases similar to original results (Tables 6 and 7).
DISCUSSION
Here, we demonstrated that aberrantly expressed cyto-
kines directed toward the development or progression of
PDAC by impairing the anti-tumor immunity and pro-
moting angiogenesis and tumor growth (Table 2). We
also showed that sMICA, thought to affect the develop-
ment and progression of PDAC through down-regulation
of NK cell antitumor function, correlated with proangio-
genic and growth-stimulatory cytokines as well as immu-
nosuppressive cytokines (Fig. 1). These results imply
sMICA is involved in tumor-associated angiogenesis and
tumor growth stimulation either directly or indirectly by
affecting corresponding cytokines as well as by causing
impairment of NK cell cytotoxicity in the development
and progression of PDAC.7
In our data, immune-associated cytokines were
shown to be mainly involved in PDAC development
rather than PDAC metastasis (Table 2), although we
could not explain the reason for this in the present study.
In regards to impairment of antitumor immunity, sMICA
correlated with IFN-c negatively (Fig. 1A). Because IFN-
c is predominantly produced by activated NK cells,17
sMICA-induced down-regulation of NK cell function can
induce reduction of IFN-c, which may aggravate the
impairment of antitumor immunity. Our results also sug-
gest the probability that serum sMICA may cause an
immunosuppressive state by increasing anti-inflammatory
cytokines (IL-10 and IL-1RA), although how sMICA
increases these cytokines cannot be explained in this
study. It is well known that PDAC spontaneously secretes
immunosuppressive substances such as IL-10.3,10,11
sMICA may be correlated with these immunosuppressive
substances under a certain mechanism, and finally induce
a positive effect on PDAC development. TNF-a, the plu-
ripotent proinflammatory cytokine, was positively associ-
ated with PDAC development in connection with sMICA
in this study (Table 2; Fig. 1A) even though it is consid-
ered to have antitumor properties. TNF-a may act as a
growth factor, as previous studies have suggested,18 and
sMICA may affect PDAC growth directly in connection
with this cytokine.
IP-10 can act as a tumor growth factor,19 although
IP-10 is generally known as an anti-tumor cytokine.
Thus, this cytokine may be associated with PDAC devel-
opment, which is inconsistent with previous reports.
Table 5. Diagnostic Accuracy of Combination Use of Serum
sMICA and Specific Cytokines to Differentiate Chronic
Pancreatitis and Pancreatic Ductal Adenocarcinoma
Variables Sensitivity Specificity
CA19-9 71.7% 76.2%
Single-marker panel
sMICA 71.7% 78.3%
IL-10 96.1% 78.3%
TNF-a 88.2% 78.3%
IP-10 78.4% 78.3%
Two-marker panel
sMICA, IL-10 97.9% 78.3%
sMICA, TNF-a 95.8% 78.3%
sMICA, IP-10 83.3% 78.3%
Three-marker panel
sMICA, IL-10, TNF-a 97.9% 82.6%
sMICA, IL-10, IP-10 97.9% 78.3%
sMICA, TNF-a, IP-10 95.8% 78.3%
Four-marker panel
sMICA, IL-10, TNF-a, IP-10 97.9% 87.0%
Abbreviations: CA19-9, carbohydrate antigen 19-9; EGF, epidermal growth
factor; cs, Spearman’s correlation coefficient; IFN-a, interferon-a; IL-1a,
interleukin 1a; IL-1RA, IL-1 receptor antagonist; IP-10, interferon gamma-
induced protein 10; MCP-1, monocyte chemotactic protein-1; PDAC, pan-
creatic ductal adenocarcinoma; sCD40L, soluble CD40 ligand; sMICA, solu-
ble MICA; TGF-a, transforming growth factor-a; TNF-a, tumor necrosis
factor-a; VEGF, vascular endothelial growth factor.
For comparison among various-sized subpanels, the cut-point ensured a
target specificity of around 80%.
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Because angiogenesis is a critical step for the initiation and
progression of PDAC,20 proangiogenic cytokines were
expected to correlate with the development and/or pro-
gression of PDAC. As expected, these cytokines, including
VEGF, sCD40L, and IL-8, correlated with the develop-
ment and/or progression of PDAC (Table 2). sCD40L,
which is known to promote angiogenesis through VEGF
induction,21 was expected to be associated with both the
development and progression of PDAC. Actually,
sCD40L was correlated with the development of PDAC
(Fig. 1B), similar to a previous study on another cancer.22
Unexpectedly, however, we did not observe a correlation
with distant metastasis. IL-8, known to stimulate tumor
growth directly or enhance angiogenesis in other can-
cers,23 was expected to be associated with both the devel-
opment and progression of PDAC. However, it did not
correlate with the development of PDAC. Rather, it corre-
lated with only the progression of PDAC in this study
(Table 2). IL-8 was closely related with sMICA in both se-
rum samples from all subjects and overt PDAC patients
(Fig. 1B,C). VEGF correlated with both the development
and progression of PDAC (Table 2), and it exhibited a
Figure 2. Receiver operator characteristic curves generated with sMICA and cytokines to predict the presence of (A) pancreatic
ductal adenocarcinoma or (B) its distant metastasis, and to (C) differentiate chronic pancreatitis from pancreatic ductal adeno-
carcinoma. AUC indicates area under the curve; CA19-9, carbohydrate antigen 19-9; EGF, epidermal growth factor; IL-8, interleu-
kin-8; IL-10, interleukin-10; IL-1RA, interleukin-1 receptor antagonist; IP10, inducible protein-10; sCD40L, soluble CD40 ligand;
sMICA, soluble major histocompatibility complex class I chain-related molecule A; TGF-a, transforming growth factor-a; TNF-a, tu-
mor necrosis factor-a; VEGF, vascular endothelial growth factor.
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strong correlation with sMICA in the development and
progression of PDAC (Fig. 1B,C). These results imply
that sMICA may be involved in tumor angiogenesis,
thereby affecting the development and progression of
PDAC.
EGF and TGF-a, which have mitogenic and mini-
mal angiogenic activities in cancer and are important
growth factors of PDAC,12,24 were shown to play impor-
tant roles in both the initiation and progression of PDAC
(Table 2). We also observed that serum sMICA was
closely correlated with these growth factors in terms of
both the development and progression of PDAC (Fig.
1B,C). These results may imply sMICA can be involved
in the direct stimulation of tumor growth by affecting
growth factors of PDAC such as EGF and TGF-a in part
in the development and progression of PDAC.
Because sMICA and cytokines are easily measurable
in serum and they show a distinct expression pattern to-
ward tumorigenesis and/or progression of PDAC, we
assumed they can be available as useful biomarkers for
predicting the presence or distant metastasis of PDAC.
Previously, we verified serum sMICA as a desirable diag-
nostic biomarker for PDAC compared to CA19-9, a con-
ventional tumor marker for PDAC.14 Here, we also
validated the diagnostic potential of the combination use
of sMICA and specific cytokines to predict the existence
of PDAC and its distant metastasis (Tables 3 and 4; Fig.
2A,B). Interestingly, we observed that combination use of
sMICA and specific cytokines exhibited superior diagnos-
tic potential for the presence and distant metastasis of
PDAC compared to CA19-9 in almost all cases (Tables 3
and 4). It also exhibited superior sensitivity/specificity for
differentiating between CP and PDAC compared to those
of CA19-9 (Table 5).
In conclusion, we demonstrated that PDAC pro-
duces many soluble factors for suppressing anti-tumor im-
munity and promoting tumor initiation and metastasis.
Table 6. Diagnostic Accuracy of Combination Use of Serum
sMICA and Pancreatic Ductal Adenocarcinoma (PDAC)-
Development–Related Cytokines to Prediction the Presence
of PDAC in the Validation Dataset
Variables Sensitivity Specificity
CA19-9 73.1% 78.6%
Single-marker panel
sMICA 88.5% 78.6%
IL-10 91.7% 84.6%
TNF-a 84.0% 78.6%
sCD40L 76.9% 78.6%
IP-10 80.8% 78.6%
Two-marker panel
sMICA, IL-10 91.7% 84.6%
sMICA, TNF-a 88.0% 78.6%
sMICA, sCD40L 88.5% 78.6%
sMICA, IP-10 80.8% 78.6%
Three-marker panel
sMICA, IL-10, TNF-a 95.7% 84.6%
sMICA, IL-10, sCD40L 91.7% 84.6%
sMICA, IL-10, IP-10 91.7% 84.6%
sMICA, TNF-a, sCD40L 96.0% 85.7%
sMICA, TNF-a, IP-10 84.0% 85.7%
sMICA, sCD40L, IP-10 88.5% 85.7%
Four-marker panel
sMICA, IL-10, TNF-a, sCD40L 95.7% 84.6%
sMICA, IL-10, TNF-a, IP-10 95.7% 84.6%
sMICA, TNF-a, sCD40L, IP-10 96.0% 85.7%
Five-marker panel
sMICA, IL-2, IL-10,
TNF-a, sCD40L
95.7% 92.3%
Table 7. Diagnostic Accuracy of Combination Use of Serum
sMICA and Specific Cytokines related With Pancreatic Ductal
Adenocarcinoma (PDAC) Progression to Predict the Presence
of Distant Metastasis of Pancreatic Ductal Adenocarcinoma
in Validation Dataset
Variables Sensitivity Specificity
CA19-9 66.7% 71.4%
Single-marker panel
sMICA 75.0% 71.4%
VEGF 66.7% 71.4%
IL-8 66.7% 71.4%
EGF 58.3% 71.4%
TGF-a 50.0% 71.4%
Two-marker panel
sMICA, VEGF 75.0% 71.4%
sMICA, IL-8 72.7% 71.4%
sMICA, EGF 75.0% 71.4%
sMICA, TGF-a 75.0% 71.4%
Three-marker panel
sMICA, VEGF, IL-8 81.8% 71.4%
sMICA, VEGF, EGF 75.0% 71.4%
sMICA, VEGF, TGF-a 75.0% 71.4%
sMICA, IL-8, EGF 81.8% 71.4%
sMICA, IL-8, TGF-a 81.8% 71.4%
sMICA, EGF, TGF-a 75.0% 71.4%
Four-marker panel
sMICA, VEGF, IL-8, EGF 81.8% 71.4%
sMICA, VEGF, IL-8, TGF-a 81.8% 78.6%
sMICA, IL-8, EGF, TGF-a 81.8% 78.6%
Five-marker panel
sMICA, VEGF, IL-8,
EGF, TGF-a
81.8% 78.6%
Abbreviations: CA19-9, carbohydrate antigen 19-9; EGF, epidermal growth
factor; cs, Spearman’s correlation coefficient; IFN-a, interferon-a; IL-1a,
interleukin 1a; IL-1RA, IL-1 receptor antagonist; IP-10, interferon gamma-
induced protein 10; MCP-1, monocyte chemotactic protein-1; PDAC, pan-
creatic ductal adenocarcinoma; sCD40L, soluble CD40 ligand; sMICA, solu-
ble MICA; TGF-a, transforming growth factor-a; TNF-a, tumor necrosis
factor-a; VEGF, vascular endothelial growth factor.
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sMICA, inducing the impairment of NK cell antitumor
immunosurveillance, may be involved in angiogenesis
and/or tumor growth either directly or indirectly through
close relationships with corresponding cytokines that are
engaged in these functions as well as down-regulation of
antitumor immunity in PDAC. Finally, we confirmed the
diagnostic usefulness of combination use of sMICA and
specific cytokines for PDAC using an independent valida-
tion dataset (Tables 6 and 7). However, relative small
sample size is still a limitation of this study. Thus, further
large-scaled prospective study is needed. Nevertheless, we
expect our results will provide valuable information to the
field of cancer immunology for which to develop new
soluble biomarkers or therapeutic approaches in PDAC.
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